Hangzhou Unogen Biotech Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of lymphoma.
Researchers at Tufts University and University of Houston System have identified receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) and/or nucleotide-binding oligomerization domain-containing protein 2 (NOD2) inhibitors reported to be useful for the treatment of multiple sclerosis.
Gilead Sciences Inc. has synthesized indoline compounds acting as viral replication inhibitors reported to be useful for the treatment of herpes simplex virus infection and herpes simplex virus encephalitis.
Researchers at Albert-Ludwigs-Universität Freiburg and Deutsches Krebsforschungszentrum (DKFZ) have disclosed drug conjugates comprising fluorescent-labeled dye covalently linked to a radionuclide and a ligand targeting glutamate carboxypeptidase II (NAALADase; NAAG peptidase, FOLH1; PSMA) acting as positron-emission tomography (PET) and fluorescent imaging agents for diagnosis and treatment of prostate cancer.
Researchers from West China Hospital of Sichuan University presented data from a study that aimed to investigate the associations between serum cystatin C (CysC) levels and the progression and survival of patients with amyotrophic lateral sclerosis (ALS).
Vandria SA has announced a series A financing round raising $20.6 million (CHF18 million) to help advance its pipeline of first-in-class small-molecule mitophagy inducers.
CD33 is known to be highly expressed in myeloid cells and a good therapeutic target for treating acute myeloid leukemia (AML). In the search for more potent compounds, researchers from Dragonfly Therapeutics Inc. and Bristol Myers Squibb Inc. investigated the therapeutic potential of BMS-986357, also known as CC-96191.
Iecure Inc. has received clearance from the Australian Therapeutic Goods Administration (TGA) of the company’s clinical trial notification (CTN) for ECUR-506 (formerly GTP-506), an investigational therapy in development for the treatment of ornithine transcarbamylase (OTC) deficiency in pediatric (or neonatal) patients.
Fibroblast activation protein (FAP) is a serine protease that is highly overexpressed in the stroma of most epithelial-derived tumors – including pancreatic, breast and colorectal cancers – in the context of cancer-associated fibroblasts (CAFs).
Simultaneous inhibition of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) is considered a good strategy in cancer treatment, although current PI3K/HDAC dual inhibitors have limitations, such as low selectivity and moderate toxicity levels.
RSS
.png?height=488&t=1670008838&width=650 "Acute myeloid leukemia")